Stay updated on BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe update is a minor version change (Revision: v3.4.2) and removal of a general government funding status notice; there are no changes to study content, eligibility criteria, primary or secondary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding was added and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedShow glossary feature was added; a new 'Last Update Submitted that Met QC Criteria' label and 'Revision: v3.4.0' were introduced. The existing items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded Moscow Oblast to the Locations section and removed the Moscow Oblast Locations. The page revision was updated to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial page.